Cardiol Therapeutics Reports Positive Phase II Findings for CardiolRx in Recurrent Pericarditis

Cardiol Therapeutics Reports Positive Phase II Findings for CardiolRx in Recurrent Pericarditis

By, Admin 8 May 2026

Cardiol Therapeutics announced that results from its Phase II study evaluating CardiolRx in recurrent pericarditis have been accepted for publication in the Journal of the American Heart Association.

The publication highlights clinical findings showing rapid and sustained reductions in pericarditis pain and inflammation, supporting continued development of the therapy in the ongoing Phase III MAVERIC trial.

Phase II Study Shows Sustained Symptom Reduction

According to the company, treatment with CardiolRx was associated with:

  • Rapid reduction in pericarditis pain
  • Sustained reduction in inflammation
  • Fewer recurrent pericarditis episodes per year
  • Favorable safety and tolerability

The study focused on patients with recurrent pericarditis who had a high baseline disease burden. The findings are expected to provide additional scientific support for the ongoing pivotal Phase III MAVERIC study, which recently surpassed 75% patient enrollment.

What Is Recurrent Pericarditis?

Pericarditis is inflammation of the pericardium, the sac surrounding the heart. The condition is often triggered by viral infections and can become recurrent, with patients experiencing repeated episodes over months or years. Symptoms commonly include:

  • Severe chest pain
  • Shortness of breath
  • Fatigue
  • Reduced physical activity
  • Repeated hospital visits

The disease can significantly impact quality of life, particularly in patients with chronic recurrences.

According to Cardiol Therapeutics:

  • Approximately 40,000 patients in the United States experience at least one recurrence annually
  • Around 60% of patients with multiple recurrences remain symptomatic for more than two years
  • One-third continue to experience disease impact after five years

Current Treatments Remain Limited

Existing treatment options for recurrent pericarditis often rely on:

  • Corticosteroids
  • Immunosuppressive therapies
  • Injectable biologics

While effective for some patients, these treatments may carry risks including:

  • Long-term dependency
  • Immune suppression
  • Significant side effects

CardiolRx is being developed as a non-immunosuppressive therapy, which could potentially offer a differentiated treatment approach.

CardiolRx Targets Inflammation Pathways

CardiolRx is designed to modulate inflammasome pathway activation, an intracellular inflammatory process linked to:

  • Pericarditis
  • Myocarditis
  • Heart failure
  • Cardiac fibrosis

The therapy is part of Cardiol Therapeutics broader strategy focused on inflammation-driven cardiovascular diseases.

Phase III MAVERIC Trial Continues Enrollment

The ongoing MAVERIC trial is a:

  • Randomized
  • Double-blind
  • Placebo-controlled
  • Pivotal Phase III study

The trial is evaluating CardiolRx for prevention of recurrent pericarditis episodes. The Phase III program builds directly on the completed Phase II MAvERIC-Pilot study and aims to further validate efficacy and safety in a larger patient population.

The therapy has also received US Food and Drug Administration Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis.

Additional Cardiol Programs Expand Pipeline

Beyond recurrent pericarditis, Cardiol Therapeutics is also advancing programs targeting other inflammatory heart diseases.

Its ARCHER program evaluated CardiolRx in acute myocarditis, a serious inflammatory heart condition associated with:

  • Acute heart failure
  • Sudden cardiac death
  • Young adult cardiovascular risk

The company is also developing CRD-38 for inflammatory heart disease and heart failure.

Why the Publication Matters?

Publication in the Journal of the American Heart Association provides independent peer-reviewed validation of the clinical findings from the Phase II study.

According to David Elsley, the publication strengthens the scientific foundation for the Phase III MAVERIC trial and supports the broader opportunity for CardiolRx in addressing unmet needs in recurrent pericarditis.

As inflammation-based cardiovascular therapies continue to attract attention, CardiolRx could emerge as a potential new treatment option for patients seeking alternatives to chronic immunosuppressive therapy.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!